期刊文献+

BNP与CA125检测在诊断慢性心力衰竭中的价值 被引量:26

The Significance of the Determination of Plasma BNP and CA125 in Patients with Chronic Heart Failure
原文传递
导出
摘要 目的探讨血浆中脑钠肽(BNP)和CA125的水平在诊断慢性心力衰竭(CHF)中的价值。方法 89例经临床确诊为慢性心力衰竭并按照纽约心脏协会(NYHA)分级区分其心衰程度的患者作为研究对象,同时选取26例健康体检人员作为对照组;采用化学免疫发光法定量测定血浆中BNP以及CA125水平;将不同组间的BNP及CA125值进行比较,并做相关性分析。结果 CHF组血浆BNP与CA125水平在心功能不同级别之间比较,差异均有统计学意义(P<0.05),并且各组间与对照组间差异均有统计学意义(P均<0.05);BNP或CA125水平与左室射血分数LVEF呈显著负相关(r值分别是-0.83和-0.61,P<0.05)。结论血浆BNP与CA125值在CHF患者中升高并与NYHA分级有明显的相关性,可作为诊断心力衰竭的有价值指标,并可用于评判慢性心力衰竭的临床治疗效果。 Objective To investigate the clinical value of BNP and CA125 in patients with chronic heart failure.Methods 89 patients diagnosed as chronic heart failure(CHF) were recruited;patients were grouped according to the New York Heart Association(NYHA) classification.26 healthy people were set as controls.The plasma BNP and CA125 were determined by chemiluminescent immunoassay.The levels of BNP and CA125 between different groups were compared,and the correlation was analyzed.Results Both of the differences of BNP and CA125 between different groups were significant(P0.01).The plasma levels of BNP and CA125 in CHF patients were negatively correlated to LVEF(r=-0.87 and-0.61,P0.05).Conclusion Levels of BNP and CA125 were correlated to NYHA classification in patients with CHF.They can be used as valuable indexes in the diagnosis and treatment of CHF.
出处 《中华全科医学》 2011年第10期1528-1529,共2页 Chinese Journal of General Practice
关键词 BNP CA125 慢性心力衰竭 BNP CA125 Chronic heart failure
  • 相关文献

参考文献11

  • 1李卫鹏,郑佐娅.B型钠尿肽研究进展[J].国外医学(临床生物化学与检验学分册),2004,25(3):260-262. 被引量:16
  • 2Chen HH, Bumett JC. Natriuretic peptides in the pathophysiology of congestive heart failure[ J ]. Curr Cardiol Rep ,2000,2 ( 3 ) : 198-205.
  • 3Groenning BA, Nilsson JC, Sondergaard L, et al. Evaluation of impaired left ventricular ejection fraction and increased dimensions by multiple nenrohumoral plasma concentrations [ J ]. Eur J Heart Fail, 2001,3 (6) :699-708.
  • 4D' Aloia A,Faggiano P,Aurigemma G,et al. Serum levels of carbohydrate antigen 125 in patients with chronic heart failure:relation to clinical severity, hemodynamic and Doppler echocardiographic abnormalities,and short-term prognosis[J]. J Am Coll Cardiol,2003,41 (10) : 1805-1811.
  • 5Kouris NT, Zaeharos ID, Kontogianni DD, et al. The significance of CA125 levels in patients with chronic congestive heart failure. Correlation with clinical and eehoeardiographic parameters[J]. Eur J Heart Fail ,2005,7 ( 2 ) : 199-203.
  • 6Kosar F, Aksoy Y, Ozguntekin G, et al. Relationship between eytokines and tumoar markers in patients with chronic heart failure [ J ]. Eur J Heart Fail ,2006,8 ( 3 ) :270-274.
  • 7Remme WJ, Swedbcrg K. Task force for the diagnosis and treatment of chronic heart failure. European society of cardiology. Guidelines for the diagnosis and treatment of chronic heart failure[ J]. Eur Heart,2001, 22 ( 17 ) : 1527-1560.
  • 8Maisel AS, Krishnaswamy P, Nowak RM, et at. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure [ J]. N Engl J Med ,2002,347 ( 3 ) : 161-167.
  • 9Dao Q, Krishnaswamy P, Kazanegra R,et al. Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting [ J ]. J Am Coll Cardiol,2001,37 ( 2 ) : 379-385.
  • 10Dmnan D,Palit F,Simsek E, et al. Serum carbohydrate antigen 125 levels in advanced heart failure:relation to B-type natriuretic peptide and left atrial volume [ J ]. Eur J Heart Fail,2008,10 (6) :556-559.

二级参考文献15

  • 1Cheung BM,Kumana CR.Natriuretic peptides-relevance in cardiovascular disease.JAMA,1998,280(23):1983-1984.
  • 2McDonagh TA,Cunningham AD,Morrison CE,et al.Left ventricular dysfunction,natriuretic peptides,and mortality in an urban population.Heart,2001,86(1):21-26.
  • 3ten-Wolde M,Tulevski II,Mulder JW,et al.Brain natriuretic peptide as a predictor of adverse outcome in patients with pulmonary embolism.Circulation,2003,107(16):2082-2084.
  • 4Colucci WS,Elkayam U,Horton DP,et al.Intravenous nesiritide,a natriuretic peptide,in the treatment of decompensated congestive heart failure.Nesiritide Study Group.N Engl J Med,2000,343(4):246-253.
  • 5Vogeser M,Jacob K.B-type natriuretic peptide (BNP)--validation of an immediate response assay.Clin Lab,2001,47(1-2):29-33.
  • 6Schulz H,Langvik TA,Lund-Sagen E,et al.Radioimmunoassay for N-terminal probrain natriuretic peptide in human plasma.Scand J Clin Lab Invest,2001,61(1):33-42.
  • 7Hughes D,Talwar S,Squire IB,et al.An immunoluminometric assay for N-terminal pro-brain natriuretic peptide:development of a test for left ventricular dysfunction.Clin Sci (Lond),1999,96(4):373-380.
  • 8Pedersen EB,Pedersen HB,Jensen KT.Pulsatile secretion of atrial natriuretic peptide and brain natriuretic peptide in healthy humans.Clin Sci (Lond),1999,97(2):201-206.
  • 9Huang WS,Lee MS,Perng HW,et al.Circulating brain natriuretic peptide values in healthy men before and after exercise.Metabolism,2002,51(11):1423-1426.
  • 10Tamura N,Ogawa Y,Chusho H,et al.Cardiac fibrosis in mice lacking brain natriuretic peptide.Proc Natl Acad Sci USA,2000,97(8):4239-4244.

共引文献15

同被引文献238

引证文献26

二级引证文献132

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部